Formosa Pharmaceuticals Investors
Shareholder Information
General Annual Meeting
Material Announcement
For related important information and material announcements, please refer to the Market Observation Post System (Symbol: 6838), URL : https://emops.twse.com.tw/server-java/t58query
Meeting Announcement
Meeting Agenda and Materials
Meeting Minutes
Annual Report
Prospectus
Stock Quote
Shareholder Contact
Common Share Transfer Agent and Registrar:
The Transfer Agency Department of KGI Securities
- Address: 4F, No.2, Sec. 1, Chongqing S. Rd., Taipei, Taiwan 10044, R.O.C.
- TEL: 886-2-23148800
- FAX: 886-2-23896042
- Website: https://www.kgieworld.com.tw/
News Highlight
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
2022-05-18
TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and Aimmax Therapeutics, Inc. (United States) announced that results from a Phase 2 clinical study of APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension), a novel